David S P Tan

ORCID: 0000-0001-9087-5262 · 9 papers in corpus
review 2026
Therapeutic advances in medical oncology ·doi:10.1177/17588359261425693

Ovarian clear cell carcinoma (OCCC) is a distinct epithelial ovarian cancer subtype with unique molecular features, and a notable resistance to conventional platinum-based chemotherapy in advanced disease. Key molecular hallmarks include fr…

observational 2024
Journal of gynecologic oncology ·doi:10.3802/jgo.2024.35.e69

OBJECTIVE: Ovarian clear cell carcinoma (OCCC) is associated with chemoresistance. Limited data exists regarding the efficacy of targeted therapies such as immune checkpoint inhibitors (ICI) and bevacizumab, and the role of secondary cytore…

review 2024
Clinical cancer research : an official journal of the American Association for Cancer Research ·doi:10.1158/1078-0432.CCR-24-1205

Clear-cell carcinomas (CCC) arising from the gynecologic tract (including from the ovary, endometrium, cervix, vulva, or vagina) represent rare but clinically significant entities with intriguing overlapping characteristics. Epidemiological…

review 2023
Frontiers in immunology ·doi:10.3389/fimmu.2023.1328651

Ovarian cancer (OC) is an aggressive malignancy characterized by a complex immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have emerged as a breakthrough in cancer therapy by reactivating the antitumor immune re…

case-report 2021
OncoTargets and therapy ·doi:10.2147/ott.s309661

BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCC…

observational 2020
Scientific reports ·doi:10.1038/s41598-020-75536-1

Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ova…

other 2019
Journal of gynecologic oncology ·doi:10.3802/jgo.2019.30.e39

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discu…

review 2013
British journal of cancer ·doi:10.1038/bjc.2013.126

Ovarian clear cell carcinomas (OCCCs) account for about 5-13% of all epithelial ovarian carcinomas in Western populations. It is characterised by resistance to conventional platinum-based chemotherapy, and new therapeutic strategies are urg…

review 2007
Journal of clinical pathology ·doi:10.1136/jcp.2006.040030

Ovarian clear cell adenocarcinomas (OCCAs) account for <5% of all ovarian malignancies. Compared to other epithelial ovarian cancer (EOC) subtypes, when at an advanced stage, they are associated with a poorer prognosis and are relatively re…